Veterinary medicinal product register

The FVS registers website is using cookies. By continuing using this website you are agreeing to use cookies.

Cookies policy

Data selected by Name Prednicortone vet

Original name

Strength

Marketing authorisation number

Marketing authorisation holder:

ATCvet code

Species

Prednicortone vet

20 mg

V/DCP/15/0025

Dechra Regulatory B.V., Nīderlande

QH02AB06

dogs; cats

Vairāk

Medicinal product information

Pharmaceutical form:	tablets
International name (active substance):	Prednisolone
Distribution category:	To be supplied only on veterinary prescription
Manufacturer(s) responsible for batch release	Lelypharma B.V., Nīderlande
Date of authorisation/renewal:	30-Jun-2020
Marketing authorisation valid until:	Unlimited time period
Marketing authorisation procedure:	DCP
Package leaflet:	[PDF] Skat_sadaļā_Zāļu_apraksts (26-Mar-2025)
Labelling text:	[PDF] Skat_sadaļā_Zāļu_apraksts (26-Mar-2025)
Summary of product characteristics:	[DOCX] Zāļu_informācija_ZA_M_LI (26-Mar-2025)

ID	Strength	Package size	Primary packaging	Labelling
V/DCP/15/0025-01	20 mg	1	Al/PE blisteris, 10 tablete	-
V/DCP/15/0025-02	20 mg	2	Al/PE blisteris, 10 tablete	-
V/DCP/15/0025-03	20 mg	3	Al/PE blisteris, 10 tablete	-
V/DCP/15/0025-04	20 mg	4	Al/PE blisteris, 10 tablete	-
V/DCP/15/0025-05	20 mg	5	Al/PE blisteris, 10 tablete	-
V/DCP/15/0025-06	20 mg	6	Al/PE blisteris, 10 tablete	-
V/DCP/15/0025-07	20 mg	7	Al/PE blisteris, 10 tablete	-
V/DCP/15/0025-08	20 mg	8	Al/PE blisteris, 10 tablete	-
V/DCP/15/0025-09	20 mg	9	Al/PE blisteris, 10 tablete	-
V/DCP/15/0025-10	20 mg	10	Al/PE blisteris, 10 tablete	-
V/DCP/15/0025-11	20 mg	15	Al/PE blisteris, 10 tablete	-
V/DCP/15/0025-12	20 mg	25	Al/PE blisteris, 10 tablete	-
V/DCP/15/0025-13	20 mg	50	Al/PE blisteris, 10 tablete	-

Prednicortone vet

5 mg

V/DCP/15/0024

Dechra Regulatory B.V., Nīderlande

QH02AB06

dogs; cats

Vairāk

Pharmaceutical form:	tablets
International name (active substance):	Prednisolone
Distribution category:	To be supplied only on veterinary prescription
Manufacturer(s) responsible for batch release	Lelypharma B.V., Nīderlande
Date of authorisation/renewal:	30-Jun-2020
Marketing authorisation valid until:	Unlimited time period
Marketing authorisation procedure:	DCP
Package leaflet:	[PDF] Skat_sadaļā_Zāļu_apraksts (26-Mar-2025)
Labelling text:	[PDF] Skat_sadaļā_Zāļu_apraksts (26-Mar-2025)
Summary of product characteristics:	[DOCX] Zāļu_informācija_ZA_M_LI (26-Mar-2025)

ID	Strength	Package size	Primary packaging	Labelling
V/DCP/15/0024-01	5 mg	1	PVH/PVdH/Al blisteris, 10 tablete	-
V/DCP/15/0024-02	5 mg	2	PVH/PVdH/Al blisteris, 10 tablete	-
V/DCP/15/0024-03	5 mg	3	PVH/PVdH/Al blisteris, 10 tablete	-
V/DCP/15/0024-04	5 mg	4	PVH/PVdH/Al blisteris, 10 tablete	-
V/DCP/15/0024-05	5 mg	5	PVH/PVdH/Al blisteris, 10 tablete	-
V/DCP/15/0024-06	5 mg	6	PVH/PVdH/Al blisteris, 10 tablete	-
V/DCP/15/0024-07	5 mg	7	PVH/PVdH/Al blisteris, 10 tablete	-
V/DCP/15/0024-08	5 mg	8	PVH/PVdH/Al blisteris, 10 tablete	-
V/DCP/15/0024-09	5 mg	9	PVH/PVdH/Al blisteris, 10 tablete	-
V/DCP/15/0024-10	5 mg	10	PVH/PVdH/Al blisteris, 10 tablete	-
V/DCP/15/0024-11	5 mg	15	PVH/PVdH/Al blisteris, 10 tablete	-
V/DCP/15/0024-12	5 mg	25	PVH/PVdH/Al blisteris, 10 tablete	-
V/DCP/15/0024-13	5 mg	50	PVH/PVdH/Al blisteris, 10 tablete	-

2 records · Download